Malaria is infection with Plasmodium species. Symptoms and signs include fever (which may be periodic), chills, rigors, sweating, diarrhea, abdominal pain, respiratory distress, confusion, seizures, hemolytic anemia, splenomegaly, and renal abnormalities. Diagnosis is by seeing Plasmodium in a peripheral blood smear and by rapid diagnostic tests. Treatment and prophylaxis depend on the PlasmodiumP. vivax and P. ovaleP. vivax or P. ovale.
Malaria is infection with Plasmodium species. About half of the world’s population is at risk of malaria. Malaria is endemic in Africa, India and other areas of South Asia, Southeast Asia, North and South Korea, Mexico, Central America, Haiti, the Dominican Republic, South America (including northern parts of Argentina), the Middle East (including Turkey, Syria, Iran, and Iraq), and Central Asia. The Centers for Disease Control and Prevention (CDC) provides information about specific countries where malaria is transmitted (see CDC: Yellow Fever and Malaria Information, by Country), types of malaria, resistance patterns, and recommended prophylaxis (see CDC: Malaria).
In 2020, there were an estimated 241 million cases of malaria, with 95% of them in Africa (see 2021 World Malaria Report). An estimated 627,000 people died from malaria in 2020, mostly children < 5 years of age. Since 2000, deaths due to malaria have decreased by approximately 30% through the efforts of the RBM (Roll Back Malaria) Partnership to End Malaria, which has > 500 partners (including endemic countries and various organizations and institutions). Despite decades of decline, the number of deaths increased in 2020 as a result of disruptions due to the COVID-19 pandemic.
Malaria once was endemic in the US. Currently, about 1500 cases occur in the US each year. Nearly all are acquired abroad, but a small number result from blood transfusions or rarely from transmission by local mosquitoes that feed on infected immigrants or returning travelers.
Pathophysiology of Malaria
The Plasmodium species that infect humans are
P. falciparum
P. vivax
P. ovale
P. malariae
P. knowlesi
Concurrent infection with more than one Plasmodium species is uncommon but can occur.
P. knowlesi is a pathogen in Southeast Asia, particularly in Malaysia. Macaque monkeys are the primary hosts. P. knowlesi is usually acquired by people living or working near or in forests.
The basic elements of the life cycle are the same for all Plasmodium species. Transmission begins when a female Anopheles mosquito feeds on a person with malaria and ingests blood containing gametocytes.
During the following 1 to 2 weeks, gametocytes inside the mosquito reproduce sexually and produce infective sporozoites. When the mosquito feeds on another human, sporozoites are inoculated and quickly reach the liver and infect hepatocytes.
The parasites mature into tissue schizonts within hepatocytes. Each schizont produces 10,000 to 30,000 merozoites, which are released into the bloodstream 1 to 3 weeks later when the hepatocyte ruptures. Each merozoite can invade a red blood cell (RBC) and there transform into a trophozoite.
Trophozoites grow, and most develop into erythrocyte schizonts; schizonts produce further merozoites, which 48 to 72 hours later rupture the RBC and are released in plasma. These merozoites then rapidly invade new RBCs, repeating the cycle. Some trophozoites develop into gametocytes, which are ingested by an Anopheles mosquito. They undergo sexual union in the gut of the mosquito, develop into oocysts, and release infective sporozoites, which migrate to the salivary glands.
Image from the Centers for Disease Control and Prevention Image Library.
With P. vivax and P. ovale (but not P. falciparum or P. malariae), tissue schizonts may persist as hypnozoites in the liver for years. Relapse of P. ovale has occurred as late as 6 years after an episode of symptomatic malaria, and the infection was transmitted by blood transfusion from a person who was exposed 7 years before donating blood. These dormant forms serve as time-release capsules, which cause relapses and complicate chemotherapy because they are not killed by most antimalarial drugs, which typically act on bloodstream parasites.
The pre-erythrocytic (hepatic) stage of the malarial life cycle is bypassed when infection is transmitted by blood transfusions, by sharing of contaminated needles, or congenitally. Therefore, these modes of transmission do not cause latent disease or delayed recurrences.
Rupture of RBCs during release of merozoites is associated with the clinical symptoms. If severe, hemolysis causes anemia and jaundice, which are worsened by phagocytosis of infected RBCs in the spleen. Anemia may be severe in P. falciparum or chronic P. vivax infection but tends to be mild in P. malariae infection.
Falciparum malaria
Unlike other forms of malaria, P. falciparum causes microvascular obstruction because infected RBCs adhere to vascular endothelial cells. Ischemia can develop with resultant tissue hypoxia, particularly in the brain, kidneys, lungs, and gastrointestinal tract. Hypoglycemia and lactic acidosis are other potential complications.
Resistance to infection
Most West Africans have complete resistance to P. vivax because their RBCs lack the Duffy blood group, which is involved in attachment of P. vivax to RBCs; many African Americans also have such resistance. The development of Plasmodium in RBCs is retarded in patients with hemoglobin S disease, hemoglobin C disease, thalassemia, G6PD deficiency, or elliptocytosis.
Previous infections provide partial immunity. Once residents of hyperendemic areas leave, acquired immunity wanes over time (months to years), and symptomatic malaria may develop if they return home and become reinfected.
Symptoms and Signs of Malaria
The incubation period is usually
12 to 17 days for P. vivax
9 to 14 days for P. falciparum
16 to 18 days or longer for P. ovale
About 1 month (18 to 40 days) or longer (years) for P. malariae
However, some strains of P. vivax in temperate climates may not cause clinical illness for months to > 1 year after infection.
Manifestations common to all forms of malaria include
Fever and rigors—the malarial paroxysm
Anemia
Jaundice
Splenomegaly
Hepatomegaly
Malarial paroxysm is caused by hemolysis of infected RBCs, released merozoites and other malaria antigens, and the inflammatory response they elicit. The classic paroxysm starts with malaise, abrupt chills and fever rising to 39 to 41° C, rapid and thready pulse, polyuria, headache, myalgia, and nausea. After 2 to 6 hours, fever falls, and profuse sweating occurs for 2 to 3 hours, followed by extreme fatigue. Fever is often hectic at the start of infection. In established infections, malarial paroxysms typically occur every 2 to 3 days depending on the species.
Splenomegaly usually becomes palpable by the end of the first week of clinical disease but may not occur with P. falciparum. The enlarged spleen is soft and prone to traumatic rupture. Splenomegaly may decrease with recurrent attacks of malaria as functional immunity develops. After many bouts, the spleen may become fibrotic and firm or, in some patients, becomes massively enlarged (tropical splenomegaly). Hepatomegaly usually accompanies splenomegaly.
P. falciparum manifestations
P. falciparum causes the most severe disease because of its microvascular effects. It is the only species likely to cause fatal disease if untreated; nonimmune patients may die within days of their initial symptoms. Temperature spikes and accompanying symptoms typically occur in an irregular pattern but can become synchronous, occurring in a tertian pattern (temperature spikes at 48-hour intervals), particularly in residents of endemic areas who are partially immune.
Patients with cerebral malaria may develop symptoms ranging from irritability to seizures and coma. Acute respiratory distress syndrome (ARDS), diarrhea, icterus, epigastric tenderness, retinal hemorrhages, algid malaria (a shocklike syndrome), and severe thrombocytopenia may also occur.
Placental involvement may lead to low birth weight, spontaneous abortion, stillbirth, or congenital infection.
P. vivax, P. ovale, P. malariae, and P. knowlesi manifestations
P. vivax, P. ovale, and P. malariae typically do not compromise vital organs. Mortality is rare and is mostly due to splenic rupture or uncontrolled hyperparasitemia in asplenic patients.
The clinical course with P. ovale is similar to that of P. vivax. In established infections, temperature spikes occur at 48-hour intervals—a tertian pattern.
P. malariae infections may cause no acute symptoms, but low-level parasitemia may persist for decades and lead to immune complex–mediated nephritis or nephrosis or tropical splenomegaly; when symptomatic, fever tends to occur at 72-hour intervals—a quartan pattern.
P. knowlesi is associated with the full spectrum of malaria. In contrast to P. falciparum, infection is more likely in males over 15 years living close to or working in forested areas. There are typically daily temperature spikes. Severity increases with the patient's age. The short asexual replication cycle of 24 hours can lead to high rates of parasitemia, and if untreated, death. Thrombocytopenia is common, but it is typically not associated with hemorrhage.
Manifestations in patients taking chemoprophylaxis
In patients who have been taking chemoprophylaxis (see table Drugs Used to Prevent Malaria), malaria may be atypical. The incubation period may extend weeks to months after the drug is stopped. Those infected may develop headache, backache, and irregular fever, but parasites may initially be difficult to find in blood samples.
Diagnosis of Malaria
Light microscopy of blood (thin and thick smears)
Rapid diagnostic tests that detect Plasmodium antigens or enzymes in blood
Fever and chills in an immigrant or traveler returning from an endemic region should prompt immediate assessment for malaria. Symptoms usually appear in the first 6 months after infection, but onset may take up to 2 years or, rarely, longer.
Malaria can be diagnosed by finding parasites on microscopic examination of thick or thin blood smears. The infecting species (which determines therapy and prognosis) is identified by characteristic features on smears (see table Diagnostic Features of Plasmodium Species in Blood Smears). If the initial blood smear is negative, additional smears should be repeated at 12- to 24-hour intervals until 3 smears are negative.
Thin blood smears stained with Wright-Giemsa stain allow assessment of parasite morphology within red blood cells (RBCs), often speciation, and determination of percentage parasitemia (parasite density), evaluated using oil immersion magnification of portions of the smear where RBCs are more or less touching, which should show about 400 RBCs per field. Thick smears are more sensitive but more difficult to prepare and interpret as the RBCs are lysed before staining. Sensitivity and accuracy of the results depend on the examiner's experience.
Commercial rapid diagnostic tests for malaria are based on the presence of certain plasmodium antigens or enzymatic activities. Assays may involve detection of a histidine-rich protein 2 (HRP-2) associated with malaria parasites (especially P. falciparum) and detection of plasmodium-associated lactate dehydrogenase (pLDH). The rapid diagnostic tests are generally comparable in sensitivity to microscopy in detecting low levels of parasitemia, but they do not differentiate single infection from concurrent infection with more than one Plasmodium species or allow speciation except for P. falciparum.
Light microscopy and rapid diagnostic tests are complementary, and both should be done when available. They have similar sensitivity. Negative results even in both does not exclude malaria in a patient with low parasitemia.
Polymerase chain reaction and species-specific DNA probes can be used but are not widely available at the point of care. They can help identify the infecting Plasmodium species after malaria is diagnosed. Because serologic tests may reflect prior exposure, they are not useful in the diagnosis of acute malaria.
Diagnostic Features of Plasmodium Species in Blood Smears
Characteristic | Plasmodium vivax* | Plasmodium falciparum | Plasmodium malariae† |
|---|---|---|---|
Infected red blood cells (RBCs) enlarged | Yes | No | No |
Schüffner dots‡ | Yes | No | No |
Maurer dots or clefts | No | Yes§ | No |
Multiple infections in RBCs | Rare | Yes | No |
Rings with 2 chromatin dots | Rare | Frequent | No |
Crescentic gametocytes | No | Yes | No |
Bayonet or band trophozoites | No | No | Yes |
Schizonts present in peripheral blood | Yes | Rare | Yes |
Number of merozoites per schizont (mean [range]) | 16 (12–24) | 12 (8–24)¶ | 8 (6–12) |
* Red blood cells (RBCs) infected with P. ovale are fimbriated, oval, and slightly enlarged; the parasites otherwise resemble P. vivax. | |||
† P. knowlesi is morphologically similar to P. malaria and has been confused with it. P. knowlesi should be considered in patients with malaria acquired in Southeast Asia, particularly in Malaysia. | |||
‡ Schüffner dots are best seen when the blood smear is stained with Giemsa stain. | |||
§ This feature is not always visible. | |||
¶ Schizonts are trapped in viscera and usually are not present in peripheral blood. | |||
Severity of malaria
Severe malaria is defined by the presence of one of more of the following clinical and laboratory features. Severe malaria tends to result from P. falciparum.
Clinical criteria for severe malaria:
Acute respiratory distress syndrome/pulmonary edema
Bleeding
Coma or impaired consciousness
Jaundice
Seizures (recurrent)
Shock
Laboratory criteria for severe malaria:
Anemia (severe: < 7 g/dL [70 g/L])
Hemoglobinuria
Metabolic acidosis
Parasite density > 5%
Renal failure
Treatment of Malaria
Antimalarial drugs
Antimalarial drugs are chosen based on the following:
Disease severity (clinical and laboratory criteria)
Infecting Plasmodium species
Known resistance patterns of strains in the area of acquisition
Efficacy and adverse effects of drugs available
Severe malariaartesunate
Due to the risk of progression to severe disease in patients with P. falciparum infection, patients should be hospitalized to monitor clinical response and to check parasite density every 12 to 24 hours until clinical presentation improves and a decrease in parasite density becomes apparent (see CDC: Treatment of Malaria: Guidelines for Clinicians [United States]).
1), hemoglobin levels should be monitored for 4 weeks after therapy.
Pearls & Pitfalls
|
In some endemic areas, a significant proportion of locally available antimalarial drugs are counterfeit. Thus, some clinicians advise travelers to remote, high-risk areas to take along a full course of an appropriate treatment regimen to be used if medically confirmed malaria is acquired despite prophylaxis; this strategy also avoids depleting limited drug resources in the destination country.
Malaria is particularly dangerous in children < 5 years (mortality is highest in those < 2 years), pregnant women, and previously unexposed visitors to endemic areas.
If P. falciparum is suspected, therapy should be initiated immediately, even if the initial smear and rapid diagnostic test are negative. P. falciparum resistance to antimalarial drugs is now widespread, and chloroquine-resistant P. vivax is common in Papua New Guinea, Indonesia, and emerging in some other areas (eg, Southeast Asia, South Asia, the Middle East, East Africa, and the Americas) (2).
For recommended drugs and doses for treatment and prevention of malaria, see tables Treatment of Malaria and Drugs Used to Prevent Malaria. Common adverse effects and contraindications are listed in table Adverse Reactions and Contraindications of Antimalarial Drugs. See also the CDC web site (Malaria Diagnosis and Treatment in the United States), or for emergency consultation about management, call the CDC Malaria Hotline at the numbers listed above.
Treatment of Malaria in the United States
Preferences | Drug a | Adult Dosage | Pediatric Dosage b |
|---|---|---|---|
Uncomplicated malaria due to P. falciparum | |||
Recommended drug | c | 6 doses (1 dose = 4 tablets) over 3 days (at 0 and 8 hours), then 1 dose twice a day for the following 2 days | 6 doses at intervals as for the adults; dose = 5–< 15 kg: 1 tablet 15–< 25 kg: 2 tablets 25–< 35 kg: 3 tablets ≥ 35 kg: 4 tablets |
or | |||
d | 4 adult tablets once a day for 3 days | < 5 kg: Not indicated 5–8 kg: 2 pediatric tablets once a day for 3 days 9–10 kg: 3 pediatric tablets once a day for 3 days 11–20 kg: 1 adult tablet once a day for 3 days 21–30 kg: 2 adult tablets once a day for 3 days 31–40 kg: 3 adult tablets once a day for 3 days > 40 kg: 4 adult tablets once a day for 3 days | |
or | |||
plus one of the following: | 650 mg 3 times a day for 3 or 7 days e | 10 mg/kg 3 times a day for 3 or 7 dayse Dose not to exceed adult dose | |
| 100 mg twice a day for 7 days | 2.2 mg/kg twice a day for 7 days | |
| 250 mg 4 times a day for 7 days | 6.25 mg/kg 4 times a day for 7 days | |
| 7 mg/kg 3 times a day for 7 days | 7 mg/kg 3 times a day for 7 days | |
Alternative (if other options cannot be used) | h | 750 mg once, then 500 mg 6–12 hours later | 15 mg/kg once, then 10 mg /kg 6–12 hours later |
Additional options for uncomplicated malaria due to P. falciparumP. malariae and P. knowlesi in all regions. If the unidentified species could be P. vivax or P. ovale | |||
Drugs i | |||
j,k | 1,000 mg, then 500 mg at 6, 24, and 48 hours | 16.6 mg/kg (up to 1000 mg), then 8.3 mg/kg (up to 500 mg) at 6, 24, and 48 hours | |
or | |||
k | 800 mg, then 400 mg at 6, 24, and 48 hours | 13 mg/kg (up to 800 mg), then 6.5 mg/kg (up to 400 mg) at 6, 24, and 48 hours | |
or | |||
c | Dosing above | Dosing above | |
Uncomplicated malaria due to P. vivaxP. ovale in all regions—Oral drugs | |||
Recommended drugs i | j,kor k | Dosing as above | Dosing as above |
plus | |||
l,m | 30 mg once a day for 14 days | 0.5 mg/kg (maximum 30 mg) once a day for 14 days | |
or | |||
l,m | 300 mg single dose | For patients ≥ 16 years, adult dose | |
Uncomplicated malaria due to P. vivaxP. vivax m (Papua New Guinea, Indonesia)—Oral drugs | |||
Recommended drugs | c | Dosing above | Dosing above |
or | |||
d | 4 adult tablets once a day for 3 days | < 5 kg: Not indicated 5–8 kg: 2 pediatric tablets once a day for 3 days 9–10 kg: 3 pediatric tablets once a day for 3 days 11–20 kg: 1 adult tablet once a day for 3 days 21–30 kg: 2 adult tablets once a day for 3 days 31–40 kg: 3 adult tablets once a day for 3 days > 40 kg: 4 adult tablets once a day for 3 days | |
or | |||
plus one of the following: | 650 mg 3 times a day for 3 or 7 days e | 10 mg/kg 3 times a day for 3 or 7 days e | |
| 100 mg twice a day for 7 days | 2.2 mg/kg twice a day for 7 days | |
| 250 mg 4 times a day for 7 days | 6.25 mg/kg 4 times a day for 7 days | |
or | |||
h | 750 mg once, then 500 mg 6–12 hours later | 15 mg/kg once, then 10 mg/kg 6–12 hours later | |
plus, with any of the above regimens | |||
l | 30 mg once a day for 14 days | 0.5 mg/kg (maximum 30 mg) once a day for 14 days | |
or | |||
l | 300 mg single dose | For patients ≥ 16 years, adult dose | |
Severe malarian, all Plasmodium —Parenteral drugs | |||
Recommended drugs | |||
n, commercially available, but if it cannot be obtained within 24 hours, contact the CDC Malaria Hotline o | Adults 2.4 mg/kg actual body weight IV at 0, 12, 24, and 48 hours | Children < 20 kg: 3 mg/kg actual body weight IV at 0, 12, 24, and 48 hours Children ≥ 20 kg: adult dose | |
Reassess parasite density 4 or more hours after third dose. When parasite density is < 1% and patient able to tolerate oral therapy, start oral treatment with one of the following: | |||
Artemether-lumefantrine (preferred) | Dosing as above | Dosing as above | |
d | Dosing as above | Dosing as above | |
f | Dosing as above; same dose may also be given IV | ||
g,p (in children < 8 years and pregnant women) | Oral dosing as above, but if parenteral therapy is required, give 10 mg/kg IV loading dose followed by 5 mg/kg IV every 8 hours | Oral dosing as above, but if parenteral therapy is required, give 10 mg/kg IV loading dose followed by 5 mg/kg IV every 8 hours | |
plus, if P. vivax or P. ovale is likely or confirmed | |||
l | 30 mg once a day for 14 days after leaving the endemic area | 0.5 mg/kg once a day (maximum 30 mg) for 14 days after leaving the endemic area | |
l | 300 mg single dose | Only for patients ≥ 16 years, use adult dose | |
a See table Drugs Used to Prevent Malaria for adverse reactions and contraindications. If malaria has developed during prophylactic drug therapy, that drug should not be used as part of the treatment regimen. | |||
b The pediatric dose should not exceed the adult dose. | |||
c | |||
d< 30 mL/min. Generally, this combination is not recommended for pregnant women, particularly during the 1st trimester, because safety data are insufficient; it may be used if other options are unavailable or are not tolerated and benefits outweigh risks. Twice a day dosing reduces nausea and vomiting as does taking it with food or milk. If patients vomit within 30 min of taking a dose, the dose should be repeated. | |||
e | |||
f Use of tetracyclines is not recommended during pregnancy and in children < | |||
g< 8 years. | |||
h | |||
i Any of the drug regimens recommended for P. falciparumP. ovale or P. vivax | |||
j | |||
k | |||
lP. vivax and P. ovale | |||
m If patients acquire P. vivaxP. vivaxP. vivax regimen, and clinicians should call the CDC Malaria Hotline. | |||
nP. falciparum | |||
o The CDC Malaria Hotline is available at 770-488-7788 or 855-856-4713 toll-free Monday-Friday 9AM to 5PM EST (after hours, weekends, or holidays, 770-488-7100). | |||
p | |||
G6PD = glucose-6-phosphate dehydrogenase; CDC = Centers for Disease Control and Prevention | |||
Adapted from the CDC: Malaria diagnosis and treatment in the United States. | |||
Adverse Reactions and Contraindications of Antimalarial Drugs
Drug | Some Adverse Reactions | Contraindications |
|---|---|---|
Headache, anorexia, dizziness, asthenia (usually mild) With lumefantrine, prolonged QT interval | During pregnancy, used if potential benefit justifies potential risk to fetus, which is usually the case in the 2nd and 3rd trimester and probably the first | |
As with artemether Delayed hemolysis; hemoglobin levels should be monitored for 4 weeks after therapy | During pregnancy, used if the potential benefit justifies potential risk, which is the case in most patients with severe malaria requiring parenteral therapy | |
Gastrointestinal disturbances, headache, dizziness, rash, pruritus | During pregnancy, used only if there are no alternatives and potential benefit justifies potential risk to fetus Hypersensitivity, breastfeeding*, severe renal impairment (creatinine clearance < 30 mL/min) | |
Gastrointestinal disturbances, headaches, dizziness, blurred vision, rashes or pruritus, exacerbation of psoriasis, blood dyscrasias, alopecia, ECG changes including prolonged QTc interval, retinopathy, psychosis (rare) | Hypersensitivity, retinal or visual field changes, or potential drug interactions, resulting in prolonged QTc interval and arrhythmia | |
Hypotension, bone marrow toxicity, renal dysfunction, rashes, jaundice, tinnitus, Clostridium difficile infection (pseudomembranous colitis) | Hypersensitivity | |
Gastrointestinal upset, photosensitivity, vaginal candidiasis, C. difficile infection (pseudomembranous colitis), erosive esophagitis | Pregnancy, children < 8 years | |
Halofantrine | Prolongation of PR and QT intervals, cardiac arrhythmia, hypotension, gastrointestinal disturbances, dizziness, mental changes, seizures, sudden death | During pregnancy, used only if potential benefit justifies potential risk to fetus Cardiac conduction defects, familial QT prolongation, use of drugs that affect QT interval, hypersensitivity |
Bad dreams, neuropsychiatric symptoms, dizziness, vertigo, confusion, psychosis, seizures, sinus bradycardia, gastrointestinal disturbances | ||
Gastrointestinal disturbances, tinnitus, visual disturbances, allergic reactions, mental changes, arrhythmias, cardiotoxicity | ||
Arrhythmias, widened QRS complex, prolonged QTc interval, hypotension, hypoglycemia | Hypersensitivity, thrombocytopenia (continuous ECG, blood pressure, and glucose monitoring recommended) | |
Severe intravascular hemolysis in people with G6PD deficiency, gastrointestinal disturbances, leukopenia, methemoglobinuria | Concomitant use of quinacrine or potentially hemolytic or bone marrow suppressing agents, G6PD deficiency, pregnancy (because G6PD status of the fetus is unknown) | |
Pyrimethamine/sulfadoxine | Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal neurolysis, urticaria, exfoliative dermatitis, serum sickness, hepatitis, seizures, mental changes, gastrointestinal disturbances, stomatitis, pancreatitis, bone marrow toxicity, hemolysis, fever, nephrosis | Hypersensitivity, folate deficiency anemia, infants ≤ 2 months, pregnancy, breastfeeding |
Severe intravascular hemolysis in patients with G6PD deficiency, psychiatric reactions, methemoglobinemia, gastrointestinal disturbances, hypersensitivity reactions | G6PD deficiency, pregnancy (because G6PD status of the fetus is unknown), breast feeding (unless child is known to have normal G6PD), psychotic disorder, known hypersensitivity For patients ≥ 16 years | |
< 5 kg. | ||
G6PD = glucose-6-phosphate dehydrogenase. | ||
Treatment references
1. Aldámiz-Echevarría LT, López-Polín A, Norman FF, et al: Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Travel Med Infect Dis 15:52-56, 2017. doi:10.1016/j.tmaid.2016.10.013
2. Ferreira MU, Nobrega de Sousa T, Rangel GW, et al: Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions. Int J Parasitol Drug-Drug Resist 15:9-24, 2021. doi:10.1016/j.ijpddr.2020.12.001
Prevention of Relapses of P. vivax or P. ovale Malaria
P. vivax or P. ovale. PrimaquineP. vivax strains are less sensitive, and relapse may occur, requiring repeated treatment. Primaquine is not necessary for P. falciparum or P. malariae because these species do not have a persistent hepatic phase. If exposure to P. vivax or P. ovale is intense or prolonged or if travelers are asplenic, a 14-day prophylactic course of primaquineprimaquine
Primaquine is contraindicated during pregnancy and breastfeeding, unless the infant has been shown not to be G6PD deficient. In pregnant women, chemoprophylaxis with weekly chloroquine
Prevention of Malaria
Travelers to endemic regions should be given chemoprophylaxis (see table Drugs Used to Prevent Malaria). Information about countries where malaria is endemic is available from the Centers for Disease Control and Prevention (CDC) (see CDC: Yellow Fever and Malaria Information, by Country and CDC: Malaria); the information includes types of malaria, resistance patterns, geographic distribution, and recommended prophylaxis.
Drugs Used to Prevent Malaria
Druga | Use | Adult Dosage | Pediatric Dosage | Comments |
|---|---|---|---|---|
b | In all areas | 1 adult tablet once a day | 5–8 kg: one-half pediatric tablet once a day > 8–10 kg: three-fourths pediatric tablet once a day > 10–20 kg: 1 pediatric tablet once a day > 20–30 kg: 2 pediatric tablets once a day > 30–40 kg: 3 pediatric tablets once a day > 40 kg: 1 adult tablet once a day | Begun 1 to 2 days before travel and continued daily during the stay and for 7 days after leaving |
Plasmodium | 500 mg once a week | 8.3 mg/kg, up to maximum 500 mg once a week | Begun 1–2 weeks before travel and continued weekly during the stay and for 4 weeks after leaving | |
c | In all areas | 100 mg once a day | ≥ 8 years: 2.2 mg/kg (up to 100 mg) once a day | Begun 1–2 days before travel and continued during the stay and for 4 weeks after leaving |
d | Plasmodium | 400 mg once a week | 6.5 mg/kg, up to 400 mg once a week | Begun 1–2 weeks before travel and continued during the stay and for 4 weeks after leaving |
e | Plasmodium | 250 mg once a week | ≤ 9 kg: 5 mg once a week > 9–19 kg: one-fourth tablet once a week > 19–30 kg: one-half tablet once a week > 30–45 kg: three-fourths tablet once a week > 45 kg: 1 tablet once a week | Begun ≥ 2 weeks before travel and continued during the stay and for 4 weeks after leaving Contraindicated in patients with a history of depression, other psychologic problems, or seizures; not recommended for patients with cardiac conduction abnormalities |
f | For primary prophylaxis for brief travel in areas known to harbor mainly P. vivax | 52.6 mg once a day | 0.8 mg/kg up to adult dose once a day | Begun 1 to 2 days before travel and continued daily during the stay and for 7 days after departure Document that the G6PD level is normal before use Contraindicated in people with G6PD deficiency and in pregnant and breastfeeding women unless the breastfed infant has a normal G6PD level |
For terminal prophylaxis to prevent relapse of infection in people with substantial exposure to or infection with P. vivax or P. ovale during travel | Dosed as above | Dosed as above | Given daily for 14 days after departure from endemic area. Document that the G6PD level is normal before use Contraindications as above | |
For primary prophylaxis in travelers to all areas | 200 mg once a day for 3 days before travel as a loading regimen, then 200 mg once weekly for maintenance while in the malaria region starting 7 days after the last loading dose, then a 200 mg final dose after exit 7 days following the last maintenance dose | For patients ≥ 16 years | G6PD deficiency or unknown G6PD status; all patients should be tested for G6PD deficiency prior to use Pregnant and breastfeeding women unless the breastfed infant has a normal G6PD level; known hypersensitivity Psychiatric adverse reactions have been observed Use with caution in patients with a history of psychiatric illness | |
For terminal prophylaxis in people with substantial exposure to or infection with P. vivax or P. ovale during travel | 300 mg single dose | Not for patients < 18 years | ||
a Preventive drugs are given orally. See table Adverse Reactions and Contraindications of Antimalarial Drugs for adverse reactions and contraindications. | ||||
b | ||||
c Use of tetracyclines is contraindicated during pregnancy and in children < 8 years. | ||||
d | ||||
e | ||||
fchloroquine-resistant malaria as treatment or prophylaxis for prolonged exposure to P. vivax and/or P. ovaleP. vivaxP. vivax | ||||
G6PD = glucose-6-phosphate dehydrogenase. | ||||
Adapted from the Centers for Disease Control and Prevention Yellow Book: Infectious diseases related to travel: Malaria. | ||||
Plasmodium species are susceptible, but there is no other safe and effective prophylactic regimen, so pregnant women should avoid travel to chloroquine-resistant areas whenever possible. Treatment of malaria during pregnancy depends on infecting Plasmodium species and known resistance patterns in the area of acquisition (see CDC: Treatment of Malaria: Guidelines For Clinicians (United States): Alternatives for Pregnant Women).
Artemisinins have a short half-life and are not useful for prophylaxis.
Prophylactic measures against mosquitoes include
Placing screens on doors and windows
Wearing protective long-sleeved shirts and pants, especially between dusk and dawn, when Anopheles mosquitoes are active
People who plan to use repellents that contain DEET should be instructed to
Apply repellents only to exposed skin as directed on the label and use them sparingly around ears (they should not be applied to or sprayed in the eyes or mouth).
Wash hands after application.
Not allow children to handle repellents (adults should apply the repellent to their hands first, then gently spread it on the child's skin).
Apply just enough repellent to cover the exposed area.
Wash the repellant off after returning indoors.
Wash clothing before wearing again unless indicated otherwise by the product label.
Most repellents can be used on infants and children < 2 months. The Environmental Protection Agency does not recommend additional precautions for using registered repellents on children or on pregnant or breastfeeding women.
On October 6, 2021, the World Health Organization (WHO) recommended widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. (See WHO recommends groundbreaking malaria vaccine for children at risk.)
Key Points
In 2020, there were an estimated 241 million people with malaria worldwide, and about 627,000 deaths occurred, mostly in children < 5 years in Africa; since 2000, deaths due to malaria have decreased by about 60%.
P. falciparum causes microvascular obstruction and tissue ischemia, particularly in the brain, kidneys, lungs, and gastrointestinal tract of nonimmune infants and adults; patients may die within days of their initial symptoms.
P. vivax, P. ovale, and P. malariae typically do not compromise vital organs; mortality is rare. The full spectrum of malaria occurs with P. knowlesi. Its short asexual replication cycle can result in high parasitemia and severe, potentially fatal disease if untreated.
Manifestations include recurrent fever and rigor, headache, myalgia, and nausea; hemolytic anemia and splenomegaly are common.
Diagnose using light microscopy of blood (thin and thick smears) and rapid diagnostic blood tests.
Treat with antimalarial drugs based on the species (if known) and drug resistance patterns in the area in which infection was acquired.
P. vivax and P. ovale to prevent relapse unless patients are pregnant, breastfeeding, have G6PD deficiency, or their G6PD status is unknown.
Severe malaria requires urgent treatment. Due to the risk of progression to severe disease in patients with P. falciparum infection, patients should be hospitalized to monitor clinical response.
Give chemoprophylaxis to travelers to endemic areas, and teach them ways to prevent mosquito bites.
More Information
The following English-language resource may be useful. Please note that THE MANUAL is not responsible for the content of this resource.
